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Background: The expression of a specific set of genes controls the different structures of heparan sulfate
proteoglycans (HSPGs), which are involved in the growth, invasion and metastatic properties of cancerous cells. The
purpose of this study is to increase knowledge of HSPG alterations in breast cancer.
Methods: Twenty-three infiltrating ductal adenocarcinomas (IDCs), both metastatic and non-metastatic were
studied. A transcriptomic approach to the structure of heparan sulfate (HS) chains was used, employing qPCR to
analyze both the expression of the enzymes involved in their biosynthesis and editing, as well as the proteoglycan
core proteins. Since some of these proteoglycans can also carry chondroitin sulfate chains, we extended the study
to include the genes involved in the biosynthesis of these glycosaminoglycans. Histochemical techniques were also
used to analyze tissular expression of particular genes showing significant expression differences, of potential
interest.
Results: No significant change in transcription was detected in approximately 70% of analyzed genes. However, 13
demonstrated changes in both tumor types (40% showing more intense deregulation in the metastatic), while 5
genes showed changes only in non-metastatic tumors. Changes were related to 3 core proteins: overexpression of
syndecan-1 and underexpression of glypican-3 and perlecan. HS synthesis was affected by lower levels of some
3-O-sulfotransferase transcripts, the expression of NDST4 and, only in non metastatic tumors, higher levels of
extracellular sulfatases. Furthermore, the expression of chondroitin sulfate also was considerably affected, involving
both the synthesis of the saccharidic chains and sulfations at all locations. However, the pro-metastatic enzyme
heparanase did not exhibit significant changes in mRNA expression, although in metastatic tumors it appeared
related to increased levels of the most stable form of mRNA. Finally, the expression of heparanase 2, which displays
anti-metastatic features, experienced a strong deregulation in all patients analyzed.
Conclusions: IDCs show alterations in the expression of HSPG genes; principally the expression and localization of
proteoglycans and the sulfation patterns of glycosaminoglycan chains, depending on the metastatic nature of the
tumor. In addition, the anti-proliferative molecule heparanase 2 experiences strong deregulation, thus highlighting
it as a potentially interesting diagnostic factor.
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Breast cancer is the most common form of cancer
reported in women in all major regions of the world, com-
prising 22.9% of all non-melanoma skin cancers, and being
responsible for 13.7% of cancer deaths in women [1]. The
most frequent type of breast cancer is the invasive (or in-
filtrating) ductal carcinoma (IDC), which accounts for
about 8 out of 10 invasive breast cancers. It starts in a
duct, breaks through the wall of the duct, and invades the
tissue of the breast, from where it is then able to
metastasize to other parts of the body.
Invasive carcinoma cells characteristically induce
changes in the adjacent stroma, and experimental evi-
dence shows that the stroma in fact actively contributes to
carcinoma progression [2]. Breast stroma accounts for
more than 80% of resting breast volume and is composed
of collagen, fibroblasts, endothelial cells, adipocytes and a
molecular network of proteoglycans (PGs) [3]. The intra-
lobular stroma, unlike the non-specialized interlobular
stroma, forms a specialized functional unit with an abun-
dance of PGs that facilitate hormonally-induced changes
in breast volume and this constitutes the backdrop to the
early stage of cancer invasion when the malignant trans-
formation of tissue takes place.
PGs are a diverse group of glycoconjugates composed of
different core proteins post-translationally modified with
linear, anionic polysaccharides called glycosaminoglycans
(GAGs) which consist of repeating disaccharides. Heparan
sulfate proteoglycans (HSPGs) comprise a specific small
group of proteins covalently linked to HS GAG
chains. HS is a complex biopolymer initially created
as a chain of alternating D-glucuronic acid (GlcA)
and N-acetyl-D-glucosamine (GlcNAc). At various posi-
tions, the molecule is modified by a series of interdepend-
ent enzymatic reactions that include N-deacetylation of
GlcNAc, usually followed by N-sulfation to produce
GlcNSO3, thus creating sulfated S-domains. Within these
regions, GlcA can be epimerized to iduronate (IdoA), and
O-sulfate groups can be added at C6 of GlcN and C2 of
IdoA residues. Minor sulfations at C3 of GlcN and C2 of
GlcA may also occur. Chain modification results in clus-
ters of flexible highly sulfated IdoA-rich regions, separated
by more rigid lowly or non-sulfated regions [4,5]. HSPGs
are ubiquitously present in tissues, mainly associated with
the cell surface and the extracellular matrix (ECM) [4,5]
and a variety of both normal and pathological functions
have been ascribed to them, including cell adhesion and
migration, organization of the ECM, regulation of prolif-
eration, differentiation and morphogenesis, cytoskeleton
organization, tissue repair, inflammation, vascularization
and cancer metastasis [4-8], the function ultimately depend-
ing on the fine structure of the chains. Specific sets of vari-
ably modified disaccharides, usually within the sulfated
domains, define binding sites for a multitude of specificligands such as cytokines, chemokines, growth factors,
enzymes and enzyme inhibitors, and ECM proteins [5,6].
Cells exercise exquisite control over HSPG composition
and sequence, though this varies between cell types, devel-
opment stages, and also as a result of cell transformation
in pathological processes. It is therefore of interest to
analyze in detail the complete set of changes in the expres-
sion of PGs and HS biosynthetic enzymes in cancer path-
ologies as well as the effect of these specific signatures on
promoting invasion and metastasis.
In several cancer cells, genes involved in the biosyn-
thesis of HSPGs are either up- or down- regulated. As
such, the upregulation of two cell-surface PGs, glypican-
1 (GPC1) and syndecan-1 (SDC1), and of the extracellu-
lar sulfatase Sulf-2, have been described in malignant
breast cancer tissues [9,10] whilst the downregulation of
some genes including SULF1 and HS3ST2 has also been
reported [11-13]. However, to date no studies have ana-
lyzed the entire set of genes involved in the synthesis of
these molecules in this pathology.
In this paper, investigation of HSPG’s biological function
in IDCs was undertaken by analyzing the expression pat-
terns of the genes involved in HSPG biosynthesis and
comparing them with healthy tissues from the same
patients. The tumors studied were subdivided into two
groups according to presence or absence of metastases in
lymph nodes since this element is a key predictor of pro-
gression. The study included genes coding for HSPG core
protein and for enzymes responsible of HS chain synthesis
and modification. Taking into account that some of these
PGs can also carry chondroitin sulfate (CS) chains, we
extended the study to the genes involved in the biosyn-
thesis of this GAG. The aim of the work was to increase
our knowledge of structural alterations of HSPGs in breast
cancer, which could be of future benefit in the develop-
ment of new chemical biology approaches to the retarding
of tumor progression through the modulation of deregu-
lated biosynthetic pathways.Methods
Materials
The following materials were purchased from the manu-
facturers indicated: RNeasy Kit and RNase-Free DNase
from Qiagen (Hilden, Germany); High-Capacity cDNA
Reverse Transcription Kit and PowerSYBR Green PCR
Master Mix from Applied Biosystems (Foster City, CA);
GenElute PCR clean-up kit and 3-30 diaminobenzidine
from Sigma-Aldrich (St. Louis, MO); Biotin 30 End DNA
Labeling Kit from Thermo Scientific (Waltham, MA); In
Situ Hybridization Detection System For Biotinylated
Probes, EnVision™ G|2 Doublestain System and Envi-
sion FLEX target retrieval solution of high pH from
Dako (Glostrup, Denmark);. All other chemicals were
Fernández-Vega et al. BMC Cancer 2013, 13:24 Page 3 of 16
http://www.biomedcentral.com/1471-2407/13/24obtained from commercial sources and were of analyt-
ical grade.
The following antibodies were used in this study: Goat
Anti-heparanase 1 (L-19), rabbit anti-sulf1 (H-81), rabbit
anti-perlecan (H-300) and rabbit anti-chondroitin 6-
sulfotransferase-2 (Z-24), all of which polyclonal antibodies
were purchased from Santa Cruz Biotechnology, Inc (Santa
Cruz, CA). Rabbit anti-heparanase-2 polyclonal antibody
from GeneTex (Atlanta, GA), and mouse monoclonal anti-
syndecan1 from DakoCytomation (Carpinteria, CA). Anti-
mouse (sc-2020), anti-rabbit (sc-2004) and anti-goat
(sc-2005) secondary antibodies were also from Santa Cruz
Biotechnology (Santa Cruz, CA).Tissue samples
We analyzed a cohort of 46 snap frozen breast samples,
obtained from the Tumor Bank at the Institute of Oncology
of Asturias (Asturias, Spain). Twenty three of the samples
were from IDCs while the remaining twenty three were
from the corresponding surrounding healthy tissue from
the same patients and were used as control. Diagnoses were
evaluated using hematoxylin-eosin-stained slides of all sam-
ples according to the World Health Organization (WHO)
criteria and the snap frozen tissues were stored at −80°C
prior to isolation of the RNA. Applying the TNM classifica-
tion, all tumors were at the T2 stage and were classified
into two groups depending on the presence (at least N1) or
absence (N0) of lymph node metastases, which resulted in
10 samples being included in the first group and 13 in the
second. The study was approved by the Ethics Committee
on Clinical Investigation of the Hospital Universitario
Central de Asturias and all patients gave their consent.Total RNA isolation and cDNA synthesis
To obtain the RNA, fragments of tissue of between 20 and
30 mg in weight were used. Samples were homogenized
using a polytron PT 2100 (Kinematica Inc; Bohemia, NY),
and RNA was isolated using the RNeasy kit, following the
manufacturer’s specifications. To ensure removal of re-
sidual contaminating DNA, samples were subjected to
treatment with RNase-free DNase during the purification
process itself. The concentration of RNA obtained was
determined spectrophotometrically by measuring absorb-
ance at 260 nm of a 1:50 dilution using a BioPhotometer
(Eppendorf; Hamburg, Germany). The samples were
divided into aliquots of 10 μl and used for reverse tran-
scription reactions or stored at −20°C until further use.
cDNA synthesis was carried out using the High Capacity
cDNA Transcription Kit following the manufacturer’s spe-
cifications. The reactions were performed using a thermo-
cycler iCycler IQ (BioRad; Hercules, CA), using 2 μg of
RNA as starting material. The reaction products were
cleaned using the PCR Clean-Up GenElute kit followingthe manufacturer’s instructions. Finally, the aliquots con-
taining the cDNA were diluted 1:20 with water and used
for qRT-PCR assays or stored at −20°C until use.qRT-PCR reactions
In all cases, specific oligonucleotides were designed
on different exons or exon junctions, using the pro-
gram Primer 3. (http://biotools.umassmed.edu/bioapps/
primer3_www.cgi). The size of the amplicon was situ-
ated in all cases between 70 and 150 base pairs, en-
suring wherever possible that the Tm was above 77°C.
The theoretical Tm for each amplicon was deter-
mined using the program Biomath (http://www.pro-
mega.com/biomath/calc11.). Primer sequences are
presented in Additional file 1.
At least four repetitions of all the qRT-PCR reactions
were carried out in a final volume of 10 μl, according to
the manufacturer’s specifications, using 1 μl of the cDNA
dilution as template, with 2 μl of primer pair mix (200 nM
final concentration) and 5 μl of SYBR Green mix all
assembled in 96 well microtiter plates. The plates were
sealed with optical film and centrifuged at 2500 rpm for
5 min before being placed in a Real-Time ABI Prism
Detection System device (Applied Biosystems; Foster City,
CA) using the following cycling conditions: 95°C for
10 min, 40 cycles of 95°C for 15 s followed by 60°C for
60 s. Following the thermal cycling and data collection
steps, amplimer products were analyzed using a melt
curve program (95°C for 1 min, 55°C for 1 min, then in-
creasing by 0.5°C per cycle for 80 cycles of 10 s each). For
each amplification the presence of a single peak with a Tm
corresponding to that previously calculated was verified.
In those cases in which the amplifications were not ad-
equate, new primer pairs were designed. Actin was
included on each plate as a control gene to compare run
variation and to normalize individual gene expression.Data analysis
To calculate the efficiencies of amplification for each
gene we used the program LinRegPCR (http://www.
gene-quantification.de/download.html), using the best
correlation coefficient (considering a minimum of 3 points
within the window of linearity) and establishing the aver-
age of all positive amplifications. At least 4 replicates of
each reactions were carried out, with the number of repli-
cates being increased in those reactions that showed am-
biguity or dispersion of results. The values of differential
expression of the genes of interest were expressed as has
been described previously [14]. A non parametric
Wilcoxon test was used for the statistical analysis of the
experiments using a level of significance of p < 0.05. All
analyses were performed using the Statistics for Windows
program (Statsoft Inc; Tulsa, OK).
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Specific sense and antisense riboprobes for NDST4,
SULF2 and HS3ST4 were designed. The riboprobe
sequences were: NDST4 sense 50- GCTGCTCCTG
CTCTGCTGTTGCTAGTGCTGCTGTGC 30, antisense 50
GCACAGCAGCACTAGCAACAGCAGAGCAGGAGCA
GxC 30; HS3OST4 sense 50- TGTGGGGAGGGAGGA
AGTCAGGGGTTGTGGGATGA 30, antisense 50 TCATCC
CACAACCCCTGACTTCCTCCCTCCCCACA 30; SULF2
sense 50 CTCGCGCTCGCCTCCAGCCACACACATTTG
CCATT 30, antisense 50 AATGGCAAATGTGTGTGGCTG
GAGGCGAGCGCGAG 30. In all cases, the length of the
probes was adjusted to between 34 and 36 nucleotides, the
content of G +C to between 48% and 62% and Tm was al-
ways above 73°C. The probes were labeled with Biotin kit
3 0End DNA Labeling Kit according to the manufacturer’s
specifications.
Chromogenic in situ hybridization (CISH)
To perform the hybridizations, tissue sections in paraffin
were treated with xylene to render them diaphanous, the
paraffin later being removed by passing it through de-
creasing alcohol concentrations until it water was reached.
The samples were then incubated at pH 9 in buffer DAKO
K8005 for 30 minutes at 90°C to facilitate the exposure of
cellular ribonucleic acid. Subsequently, the preparations
were washed with sterile tris-buffered saline (TBS), and
incubated with labeled probes at a dilution of 1:2.5 in
sterile water in a DAKO hybridization oven for 5 minutes
at 95°C, followed by 15.5 hours at 62°C. Then, the pre-
parations were washed with TBS for 10 minutes, followed
by a second wash for a further 5 minutes. The entire
procedure was carried out using the In Situ Hybridization
Detection System for Biotinylated Probes according to
the manufacturer’s specifications. Sections were fixed,
mounted and examined with a Leica DMR microscope
(Wetzlar,Germany). Visualization was carried out using a
DFC295 Leica camera.
Inmunohistochemistry
Tissue sections were dewaxed as described in the previous
section. Rehydrated sections were rinsed in phosphate buf-
fered saline (PBS) containing 1% tween-20. For detection of
sulfatase-1, heparanase 2, chondroitin 6-sulfotransferase-2
and perlecan, sections were heated in high pH Envision
FLEX target retrieval solution at 65°C for 20 min and then
incubated for 20 min at room temperature in the same so-
lution. For detection of heparanase the final step was
omitted.
Endogenous peroxidase activity (3% H2O2) and non-
specific binding (33% fetal calf serum) were blocked and
the sections were incubated overnight at 4°C with primary
antibodies using a 1:100 dilution. Secondary antibodies
were used at a 1:100 dilution. 3-3’ diaminobenzidine wasused as a chromogen. Selected slides were lightly counter-
stained with haematoxylin.
Results
Analysis of differential gene expression
We investigated the differential expression of the genes
involved in defined steps of the biosynthesis of HSPGs
in IDCs dividing the sample into two depending on the
presence or absence of metastases in the lymph nodes.
13 samples were obtained from patients lacking metas-
tases; their mean age was 60 ± 12 years; histological grade
in all cases was moderate-low; the average tumor size was
2,08 ± 0,9 × 1,35 ± 0,6 cm; 90% were luminal A; 65% were
located in the upper outer quadrant and 7.5% showed vas-
cular invasion.
In addition, 10 samples were obtained from patients
who showed lymph node metastases in 100% of cases,
their mean age was 58 ± 14 years; histological grade was
moderate-high; the average tumor size was 3,7 ± 0,4 ×
3,11 ± 1,9 cm; The percentage of luminal A was 60%;
only 20% were located in the upper, outer quadrant and
80% showed vascular invasion.
We used qRT-PCR to perform a quantitative analysis
of mRNA expression. In many of the genes in which we
were able to detect differences between normal tissues
and tumors we complemented the studies determining
the expression by histological techniques by including in
situ hybridizations and Inmunohistochemistry.
Differential expression of genes encoding core proteins
carrying HS chains
Only 13 genes encode HSPG core proteins. Two gene
families, syndecans and glypicans, account for most cell
surface HSPGs. Respectively these families comprise 4
(SDC1-4) and 6 (GPC1-6) different proteins. The three
remaining molecules are arranged in the extracellular
matrix and include perlecan (PRCAN), agrin (AGRN)
and collagen type XVIII (COL18A1) [15]. Within the
syndecans group, no significant differences in the tran-
script levels of species 2, 3 and 4 could be detected
(Figure 1A and 1B); however, Syndecan-1 displayed a
more than two fold overexpression in both metastatic
and non metastatic (p = 0.013 and 0.028 respectively)
tumors (Figure 1C); overexpression occurred in 60% of
the cases of non-metastatic IDCs analyzed and in 75% of
the metastatic. Changes in Syndecan-1 were also evalu-
ated immunohistochemically using monoclonal anti-
SDC1. Healthy tissue analysis showed intensive staining
on the baso-lateral surface of epithelial cells of ducts and
acini in duct-lobular units, with local staining in myoe-
pithelial cells (Figure 2A). Furthermore, IDCs displayed
positive immunoreactivity on the basal side of ducts, as
well as intense staining of the stroma, regardless of the
nature of the tumor (Figure 2B and 2C).
Figure 1 Differential transcription of genes encoding HSPGs.
(A,B) Relative transcript abundance of mRNAs for HSPGs. Relative
abundance for healthy tissues (gray bars) and tumors (black bars) are
plotted on a log scale for each gene assayed and the spreads
represent the standard deviations. (A) Non-metastatic IDCs. (B)
Metastatic IDCs. (C) Relative expression ratio of genes that show
statistically significant differences in expression in non-metastatic (●)
or metastatic (■) IDCs. Values on the Y axis are represented on a
logarithmic scale.
Fernández-Vega et al. BMC Cancer 2013, 13:24 Page 5 of 16
http://www.biomedcentral.com/1471-2407/13/24Analysis of the expression levels of all the different Glypi-
cans showed substantial differences between them, much
wider than for the Syndecans, reaching up to nearly 3
orders of magnitude, with Glypican-1 being the most
abundant species. The qRT-PCR results were unable to
detect significant diferences in the levels of transcripts ex-
cept for Glypican-3 (GPC3), in which 85% of non-
metastatic (p = 0.003) and all metastatic tumors (p = 0.005)evidenced a strong (approximately 10 fold and 12 fold re-
spectively) sub-expression (Figure 1C).
When evaluating the extracellular matrix PGs, no signifi-
cant differences were detected for agrin and collagen XVIII.
However, perlecan experienced significant down regulation
of expression in 70% of non-metastatic (p = 0.002) and 90%
of metastatic cases (p = 0.01). The values of reduced relative
abundance of mRNA ranged from over 3 times more in
non-metastatic IDCs to up to 6 times more in metastatic
tumors (Figure 1C). In the same vein, immunofluorescence
staining confirmed that expression of perlecan protein was
reduced in tumor tissue compared to in the surrounding
healthy tissue (Figure 2D and 2E).Expression of enzymes involved in the biosynthesis of HS
chains
HS and CS/DS chains are synthesized by cooperation of
multiple biosynthetic enzymes in the Golgi. This study
included the genes which code glycosyltransferases (GTs)
involved in HS chain polymerization, including EXTL2, re-
sponsible for transferring the first GlcNAc residue, and
EXT1 and EXT2, which encode copolymerases for chain
extension. None of the genes showed changes in their
transcript levels in IDCs (Figure 3).
The result of the activity of all GTs involved in the syn-
thesis of HS is an unmodified chain made of GlcA-GlcNAc
repeating units. As the chain polymerizes, it undergoes sev-
eral modifications; the initial ones involve removal of acetyl
groups from GlcNAc residues, followed by sulfation of the
amino group which is catalyzed by four different isoforms
of N-deacetylase/N-sulfotransferases, NDST1, NDST2,
NDST3 and NDST4 [4,16]. Transcripts of only two of these
isoforms, NDST1 and 2, were able to be quantified in all
healthy tissues, while NDST3 and 4 were undetectable in
most patients (Figure 3A and 3B). When the analysis was
conducted in tumor tissues, no significant differences of
transcript levels of isoforms 1 and 2 were detected
(Figure 3A and 3B). In addition, NDST3 did not show clear
alteration patterns, although its low expression did not
allow for definitive conclusions to be drawn. Interestingly,
NDST4 transcription increased, and its expression was
detected in 50% of patients, both metastatic and non meta-
static (Figure 3). CISH studies confirmed this result, since
tumors expressing NDST4 showed a positive hybridization
of tumoral cells that was absent in normal cells (Figure 4A).
Further modifications of the HS chain include the epi-
merization of GlcA into IdoA, catalyzed by the action of
the enzyme C5-GlcA epimerase (GLCE), the addition of
sulfate groups at C2 of uronic acid, catalyzed by the
enzyme HS 2-O-sulfotransferase (HS2ST1), and the
addition at C6 of glucosamine residues, catalyzed by HS
6-O-sulfotransferase isoforms 1–3 (HS6ST1, HS6ST2 and
HS6ST3) [4,16]. None of these enzymes showed statistically
Figure 2 Inmunohistochemistry of HSPGs. (A-C) Localization of syndecan-1 using inmunhistochemistry in normal and tumoral breast tissue.
(A) Normal tissues showing sydecan expression exclusively in the terminal ductal lobular unit, magnification 200X. (B,C) Non-metastatic and
metastatic tumors, respectively,showing an increased expression of syndecan-1 in the desmoplastic stroma, magnification 100X. (D) Control of
syndecan antibodies. IDC in area of chronic inflammatory reaction, where some plasmatic cells are present. They show strong positivity to
syndecan (arrow). (E,F) Confocal microcopic visualization of perlecan (green) in IDC. The cytoplasm was stained with TriC-conjugated phalloidin
(red) and nuclei counterstained with DAPI (blue). (D) Normal breast tissue. (E) Metastatic tumor tissue, magnification 600X.
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and 3B).
The last step in the modification of HS chains during
biosynthesis in the Golgi involves the addition of sulfate
group at C3 of glucosamine. This reaction is catalyzed by
HS 3-O-sulfotransferase isoforms 1–6 (HS3ST1, HS3ST2,
HS3ST3A1, HS3ST3B1, HS3ST4, HS3ST5 and HS3ST6)
[17]. In non metastatic IDCs, isoforms 4, 5 and 6 exhibited
an approximately 8, 5 and 10 fold downregulation respect-
ively (p = 0.009, 0.01 and 0.01). Meantime, in metastatic
tumors, while isoform 5 was not altered, there was a 10
fold reduction in expression of isoform 6 (p = 0.008), andisoform 4 down regulation (p = 0.02) increased more than
30 fold (Figure 3C). We carried out CISH studies with bio-
tinylated probes for HS3ST4 which confirmed a decrease
in staining in the tumoral cells relative to normal tissue
(Figure 4B).
The final modification of the HS patterning is carried out
at the cell surface by two cell surface sulfatases, SULF1 and
SULF2, which remove GlcN-6S groups from specific
regions [17]. The transcript levels of both enzymes were
overexpressed in non metastatic IDCs (p = 0.007 and 0.01
respectively, Figure 3). Interestingly, no significant
differences could be detected in metastatic tumors.
Figure 3 Differential transcription of genes encoding enzymes involved in the biosynthesis of HS repeating unit. (A,B) Relative transcript
abundance of mRNAs for enzymes involved in the synthesis of HS chains. Relative abundance for healthy tissues (gray bars) and tumors (black
bars) are plotted on a logarithmic scale for each gene assayed and spreads represent the standard deviations. (A) Non-metastatic IDCs. (B)
Metastatic IDCs. (C) Relative expression ratio of genes that show statistically significant differences in expression in non-metastatic (●) or
metastatic (■) IDCs. Values on the Y axis are represented on a logarithmic scale. NDST4 was not detected in healthy tissues.
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and SULF2 respectively corroborated this data, showing
stronger staining in tumor cells relative to healthy ones
(Figure 4C and 4D,E).
Expression of enzymes involved in the biosynthesis of CS
chains
We analyzed the transcription levels of genes involved in
the polymerization of CS chains, including CSGAL-
NACT2, responsible for transferring the first N-acetyl-
galactosamine (GalNAc) residue, and the chondroitin
synthases CHSY1, CHPF and CHSY3 [17]. With one ex-
ception, none of these genes showed changes in their tran-
script levels in either non-metastatic or metastatic IDCs
(Figure 5A and 5B). The exception was CSGALNACT2,which was downregulated approximately 4 and 7 fold in
non-metastatic (p = 0.01) and metastatic (p = 0.02) IDCs
respectively (Figure 5C).
CS chains are modified to a lesser extent than those of
HS. Possible reactions include epimerization of GlcA in
CS chains, which results in dermatan sulfate (DS) chains,
catalyzed by DSE; addition of sulfate groups at C2 of IdoA
residue of DS, catalyzed by chondroitin uronosyl sulfo-
transferase (UST); sulfation at C4 of GalNAc, catalyzed by
different isoenzymes with specificity for CS or DS chains
(CHS11, CHS12, CHS13, CHS14), and addition of sulfate
at C6 of GalNAc, also catalyzed by different isoenzymes
(CHS3, CHS7); sulfation at C6 may also occur in pre-
sulfated residues catalyzed by a N-acetylgalactosamine
4-sulfate 6-O-sulfotransferase (CHS15) [18].
Figure 4 Localization of enzymes involved in the modification of HS chains. (A) CISH for NDST4 in IDC, negative for two ducts of normal
appearance (arrows) and positive for the rest of the tissue, mainly consisting of tumor cells, magnification 200X. (B) CISH for HS3OST4 in IDC. The
terminal ductal lobular unit showing an intense reactivity (arrow) while the staining patterns are less intense in tumor cells, magnification 100X.
(C) CISH for SULF2 in IDC. At the bottom right unstained normal breast ducts are seen (arrow). Some adipose tissue is also present. Hybridization
is positive for the rest of the tissue, constituted by tumor cells, magnification 100X. (D,E) Inmunohistochemistry for SULF1 in IDC. (D) Healthy
tissue, terminal ductal lobular unit, magnification 200X (E) Intense immunostaining in tumor cells that grow into irregular ducts with lights,
magnification 400X.
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be detected, but several reduced relative abundances of
mRNA involving genes responsible for the sulfation at dif-
ferent locations were. C2 of IdoA residues seemed to be
undersulfated since UST transcription decreased 4 fold
both in non metastatic (p = 0.01) and metastatic (p = 0.01)
IDCs (Figure 5). Sulfation at C4 of GalNAc appeared to be
selectively affected since one of the chondroitin 4-O-sulfo-
transferases, CHS12, decreased 3 fold in non metastatic
tumors (p = 0.02) and around 10 fold (p = 0.009) in meta-
static IDCs (Figure 5). However, what did appear to be
affected in a generalized form was the generation of
GalNAc(6S) residues given that the transcription of the
two genes coding the enzymes that catalyze this reaction,
CHST3 and CHST7, decreased in both non metastatic
(p = 0.003 and 0.003 respectively) and metastatic
(p = 0.009 and 0.01) IDCs (Figure 5). Inmunohistochem-
ical studies were performed for CHST3 using specific anti-
bodies; these analyses allowed us to visualize the decreasein immunostaining as tumor cell proliferate in relation to
healthy tissue (Figure 6A-C).
Expression of heparanases
Heparanase (HPSE) is an endo-β-D-glucuronidase that
degrades HS, generating biologically active fragments. This
enzyme, along with the previously mentioned SULF1 and
SULF2, constitutes what are known as the editing
enzymes, responsible for modification of HS fine structure
in physiological and pathological processes. We analyzed
its transcription in relation to the presence or absence of
metastasis in IDCs. The structure of the HPSE gene is
represented in Figure 7; it spans over 50 kb and consists
of 14 exons [19]. Performing qRT-PCR reactions, we failed
to detect significant changes in HPSE transcription either
in metastatic or non metastatic IDCs (Figure 8), thereby
apparently disagreeing with previous reports indicating
overexpression of this enzyme, especially in metastatic
tumors [20]. Our initial experiments were carried out
Figure 5 Differential transcription of genes encoding enzymes
involved in the biosynthesis of CS repeating unit. (A,B) Relative
transcript abundance of mRNAs for enzymes involved in the
modification of CS chains. Relative abundance for healthy tissues
(gray bars) and tumors (black bars) are plotted on a logarathmic
scale for each gene assayed and spreads represent the standard
deviations. (A) Non-metastatic IDCs. (B) Metastatic IDCs. (C) Relative
expression ratio of genes that show statistically significant
differences in expression in non-metastatic (●) and metastatic (■)
IDCs. Values on the Y axis are represented on a logarithmic scale.
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performed new reactions using primers located in exons 9
and 10, with similar results (Figure 8).
Possible alterations in the noncoding regions of mRNA
that could influence the expression levels were also ana-
lyzed. Two mRNA species containing the same ORF,
HPSE1a, and HPSE1b, generated by alternative splicing,
have been described [19]. Both species differ in the struc-
ture at their 50 end, which helps to differentiate them using
appropriate primers (Figure 7A). qRT-PCR reactionsindicated that the isoform HPSE1a was expressed in both
healthy and tumor tissues, while HPSE1b remained at very
low or undetectable levels (Figure 8A and 8B).
Recent research has identified the existence of a 185-bp
sequence within the 30 untranslated region that mediates
HPSE down-regulation [21]. We designed probes to detect
the presence of this alteration in the 30 end (Figure 7B).
The results indicated that both forms could be detected,
although the shorter species was the most abundant in all
cases (more than two fold, Figure 8A and 8B). Comparison
of expression levels of each of the transcripts did not evi-
dence any significant differences between tumors and
healthy tissue. However, when the relative expression
levels of both forms (short form / long form expression
ratio) were subjected to statistical analysis, there was in-
deed no significant difference in non-metastatic tumors,
but there was in fact a change in metastatic relative to
healthy tissues (p = 0.02), suggesting a higher relative pro-
portion of the short isoform in this group of IDCs
(Figure 8C). Alterations in the expression of HPSE were
also determined in tissue arrays by immunohistochemistry
and demonstrated the existence of varying levels of pro-
tein overexpression in different patients (Figure 9A-D).
Heparanase 2 (HPSE2) is a homologue of HPSE that
lacks HS-degrading activity, although it is still able to
interact with HS with high affinity [20]. Using a pair of
probes designed to anneal to common regions in all iso-
forms predicted for this gene, we were able to detect a
significant transcription alteration which appeared
down-regulated approximately 30 fold (p = 0.01 and
0.007) in all types of IDCs (Figure 8A and 8B). It has
been previously described that wild-type heparanase 2
(HPSE2c) exhibits very high affinity for HS, and is able
to compete with HPSE. To check the expression levels
of this isoform, we performed qRT-PCR reactions using
probes against exons 3 (absent in isoform HPSE2b) and
4 (absent in isoforms HPSE2b and HPSE2a). The results
were again of note, indicating as they did a 30 fold de-
crease in the expression of (p = 0.01) in IDCs (Figure 8A
and 8B). Immunohistochemical studies confirmed this
result, with tissues from all patients analyzed showing a
decrease in immunoreactivity for antibodies specific for
HPSE2 (Figure 9E and 9F).
Discussion
The expression of HSPGs is markedly altered during ma-
lignant transformation and tumor progression, affecting
both the PG core proteins and the GAG chains [13]. The
HS fine structure can be determined by cell-type specific
expression of only certain isoforms of some biosynthetic
enzymes (Figure 10), notwithstanding the existence in
some specific cases of regulation at translation level or en-
zymatic catalysis [21-24]. In this paper we investigated the
expression patterns of the genes involved in HSPG
Figure 6 Inmunolocalization of chondroitin 6-O-
sulfotransferase 1. (A) Typical terminal ductal lobular unit of the
breast displaying an intense cytoplasmic immunoreactivity for
CHST3. Perilobulillar inflammatory cells are not marked. (B) Breast
duct with IDC showing cytoplasmic immunoreactivity only in cells of
the basal layer. (C) Group of epithelial cells that proliferate
haphazardly, infiltrating the adjacent adipose tissue. It is a IDC in
which there is little immunoreactivity for CHST3, magnification 400X.
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from the same patients. The tumors were subdivided into
two groups according to presence or absence of metasta-
ses in the lymph nodes, given this is the principal indicator
of cancer progression.
In human cells, there are 13 genes encoding “full-
time” HSPGs, although a few more may appear as “part-
time” ones [4,5]. Only SDC1 from the syndecan group
appeared overexpressed more than two fold in both
metastatic and non metastatic tumors. Upregulation of
SDC1 has been previously described in breast cancer, al-
though with values exceeding 10 times those of the nor-
mal tissue, as determined by immunohistochemical
staining quantification [25]. Our analysis of tumor and
healthy tissue sections using monoclonal anti-SDC1 dis-
played an intense Immunoreactivity of the tumoral
stroma regardless of the nature of the tumor, although
this was more intense in metastatic IDCs, and lesser
staining of the basement membrane of ducts.
This result represents a change in the location of the
expression of SDC1 compared to healthy tissue, where
immunoreactivity was displayed mostly on the baso-
lateral surface of epithelial cells of ducts and acini in
duct-lobular units. The shift of SDC1 from epithelial to
stromal cells during progression of breast tumors has
been previously reported, and suggested to stimulate
carcinoma growth and angiogenesis [26,27]. Moreover,
the existence of differences between transcript levels
quantified by qRT-PCR and immunostaining found in
the present study could be an indicator of additional
post-transcriptional regulation of SDC1 expression,
which has been described for certain cell types [24].
Upregulation of SDC1 has also been described in other
tumors such as pancreatic, lung and brain cancer, and it
has been postulated that this aberrant expression may
play a key role in promoting growth factor signaling in
cancer cells [13]. Interestingly, SDC1 is downregulated
in various malignances, such as colorectal cancer, indi-
cating that this HSPG may serve as a prognostic marker
in a cancer-type-specific manner [13].
No significant differences in the levels of transcripts of
isoforms 2, 3 and 4 were detected in this study, although
overexpression of SDC4 has been previously described
for an estrogen receptor-negative highly proliferative
breast carcinoma subtype [28]; however, most samples
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which constitutes a common early stage of breast cancer
where tumors have higher levels of estrogen and proges-
terone receptors.
Glypicans influence tumor progression and their ex-
pression is abnormal in various human tumors [22]. The
analysis of the expression of the 6 protein isoforms in
tumors only showed significant differences for GPC3.
GPC3 transcription was downregulated in 85% of non-
metastatic and 100% of metastacic IDCs, with its levels
decreasing about 10 and 12 fold respectively. Previous
reports have detected similar results [22,29], comparable
with those found for other tumor types, including lung,
gastric, ovarian cancer and mesothelioma [22]. GPC3
plays a negative role in cell proliferation, and its deple-
tion may contribute to cancer progression, although
results for tumors originating from tissues expressing
GPC3 in the embryo only, suggest its expression tends
to occur together with malignant transformation [22].
Of the three extracellular matrix proteins, only perle-
can evidenced a significant alteration of its transcript
levels being downregulated 3 fold in non-metastatic
IDCs and close to 6 fold in metastatic tumors. Perlecan
is a critical regulator of growth factor-mediated signaling
and angiogenesis, and is fundamental for the mainten-
ance of basement membrane homeostasis [30], and as
such its alteration could play important roles in IDC
progression. Although expression of perlecan is
enhanced in a number of tumor types, its levels are un-
detectable in some other instances such as lung carcin-
oma and in hepatocellular carcinoma cells [31]; in these
latter cases, lack of perlecan has been suggested toFigure 7 Genomic organization of HPSE gene. Numbered boxes represe
represent the 50 and 30 untranslated regions. The black region represents th
primers is indicated by arrows. (A) 50 end of isoforms HPSE1a and HPSE 1b.
region that mediates HPSE down-regulation.perhaps favour the diffusion of growth factors, leading
to tumor growth and metastasis [31].
Most, if not all, HSPGs can be hybrid molecules, car-
rying both HS and CS side chains [15]. To generate
GAG chains requires the regulated expression and ac-
tion of multiple GTs, which are arrayed in the lumen of
the Golgi apparatus [4] (Figure 10A). Analysis of differ-
ential transcription of polymerases involved in the syn-
thesis of HS chains (EXTL2, EXT1, EXT2) and CS chains
(CSGALNACT1, CHSY1, CHPF, CHSY3) did not show
any significant difference except for CSGALNACT1,
which was down regulated arround 3 fold in both groups
of IDCs. This gene encodes a chondroitin β1,4 N-acetyl-
galactosaminyltransferase which acts immediately after
synthesis of the linkage tetrasaccharide and directs the
synthesis towards the polymerization of CS chains.
Competition exists between this reaction and the
addition of a α1,4-linked GlcNAc, that directs the syn-
thesis towards the polymerization of HS chains, such
that the decline observed in this study would suggest a
decrease of CS in relation to HS. Variations in the levels
of GAGs in different tumors have previously been
described, both increases and decreases. Also, in certain
types of breast tumors, such as pericanalicular fibro-
adenoma, low levels of GAGs have been observed, par-
ticularly CS, while in intracanalicular fibroadenoma or
scirrhous carcinoma the CS content increases but, inter-
estingly, in no case have alterations in the levels of HS
been detected [32]. The relative levels of galactosamino-
glycans in these tumors have been suggested to have a
close relationship with the fibrogenesis in the interstitial
stromal elements [32].nt the 14 exons. Gray boxes represent the ORF and white boxes
e sequence of intron that form part of HPSE 1b. The location of PCR
(B) Location of the 185-bp sequence within the 30 unstranslated
Figure 8 Differential transcription of genes encoding
heparanases. (A,B) Relative transcript abundance of mRNAs for
HPSE and HPSE2 isoforms. Relative abundance for healthy tissues
(gray bars) and tumors (black bars) are plotted on a logarithmic
scale for each gene assayed and spreads represent the standard
deviations. (A) Non-metastatic IDCs. (B) Metastatic IDCs. (C) Relative
transcript abundance of 30 UTR isoforms of heparanase in healthy
tissues and non-metastatic and metastatic IDCs plotted on a linear
scale.
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action of multiple sulfotransferases and an epimerase
(Figure 10B). The initial modification reaction involves
removal of acetyl groups from GlcNAc residues, fol-
lowed by sulfation of the amino group catalyzed by four
different isoforms of N-deacetylase/N-sulfotransferases
[4,16], a reaction essential for the creation of sulfated
S-domains. NDST1 and NDST2 show broad overlapping
tissue distribution [18], have both been detected in
breast tissue, but our results showed no significant dif-
ferences of transcript levels in IDCs. NDST3 and
NDST4, on the contrary, are expressed primarily during
embryonic development [33]. In the present study nei-
ther of these isoforms were detected in healthy tissues;
Furthermore, NDST3 was only detected at very low
levels and only in a small number of patients, making it
difficult to draw conclusions. NDST4 transcripts were,
however, detected in 50% of tumors, both metastatic and
non metastatic, a finding confirmed by subsequent CISH
studies which selectively detected the presence of
NDST4 transcripts in tumoral cells and not in normal
cells. NDST4 has been described as possessing different
enzymatic properties to those of NDST1 and NDST2, in
so far as it displays weak deacetylase activity but high
sulfotransferase [34].
Further modifications of HS chains include the action of
C5-GlcA epimerase and 2-O-sulfotransferase [5], and the
sulfation at C6 of GlcN residues, catalyzed by HS 6-O-
sulfotransferases [35]. There were no significant differ-
ences in tumor expression for any of these in the present
work.
The last family of enzymes involved in HS modifica-
tion are the 3-O-sulfotransferases, which add a sulfate
group to C3 of already sulfated glucosamine residues [5].
In several cancers, including breast, a HS3ST2 gene
silenced via methylation has been reported [12,36]; how-
ever, in this study, the transcription of this gene was only
downregulated in about 45% of cases analyzed. Never-
theless, HS3ST6 displayed significant differences, appear-
ing to be downregulated about 10 fold in more than 80%
of metastatic and non-metastatic IDCs. HS3ST4 was the
isoform that showed the lowest transcription levels, con-
firming previous data showing low levels of expression
of this isoform in most tissues, except in cerebral cortex
Figure 9 Inmunohistochemistry of heparanases. (A-D) Immunohistochemistry of HPSE. (A-D). Series of images showing the heterogeneous
patterns of expression of HPSE in IDCs from negative staining (A), weak staining (B), moderate staining (C) and strong staining (D). Weak staining
of breast normal tissue is indicated by an arrow (D); magnification A-C 400X, D 100X. (E,F) Immunohistochemistry of HPSE2. (E) Image of at least
three terminal ductal lobular unit displaying immunostaining, mainly in the myoepithelial cells of ducts and acini. A slight reactivity in acinar and
ductal cells can also be detected. (F) Tumor tissue forming ducts of different sizes and irregular light: The immunoreactivity for the antibody
against HPSE2 is very low, magnification 200X.
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http://www.biomedcentral.com/1471-2407/13/24and cerebellum [37]. Its transcription also displayed sig-
nificant differences, exhibiting an 8 fold under-
expression in 75% of metastatic tumors, and of more
than 30 fold in 90% of metastatic. Finally, HS3ST5 also
appeared to be expressed only at low levels, again con-
firming previous findings of its low expression in all tis-
sues [37]. Its transcript levels also displayed significant
decreases, although only in the group of non-metastatic
IDCs. Whilst the implications of 3-O-sulfation decrease
in tumors are not yet known, it has been suggested that
certain patterns of 3-O-sulfation could impart cancerous
phenotypic changes [13].
Of the different sulfate groups present on the HS chains,
6S modification is the only sulfate moiety known to be
post-synthetically edited from the chain [38], by a set of
HS 6-O-endosulfatases localized in the cell surface, SULF1
and SULF2. The analysis of both genes in IDCs showed
significant differences in non-metastatic tumors, in which
both appeared overexpressed in 70% of the cases analyzed.
By contrast, in metastatic tumors the percentagedecreased to 40%. Overexpression of these genes has been
previously reported in other tumors such as pancreatic
cancer [13]. With regard to breast cancer, previous studies
indicate an upregulation of SULF2 [10], while SULF1 has
been found to be down regulated in some breast cancer
cell lines [11], although in our study we could only detect
a small reduced relative abundance of mRNA of SULF1 in
less than 10% of the cases analyzed. The alterations in sul-
fation patterns in tumors have been suggested to perhaps
be related with protecting the cancer cell from Natural
Killer (NK) recognition [13].
As indicated before, HSPGs can be hybrid molecules,
carrying both HS and CS side chains [15]. However, the
alterations observed in transcriptions of GTs seem to
point to changes in the CS chains. In addition, changes
in CSPGs associated with breast cancer have been
described, such as decorin or CSPG4 [39,40]. CS/DS
chain modifications involve 4-sulfotransferases that dif-
ferentiate between CS and DS (Figure 10C) [40,41]:







































Figure 10 Biosynthesis of heparan sulfate and chondroitin sulfate structures. (A) GTs involved in HS and CS biosynthesis. (△) xylose; (▲)
galactose; (♢) GlcA; (□) GlcNAc (■) GalNAc. (B) Modification genes involved in HS biosynthesis and edition. (C) Modification genes involved in CS
biosynthesis.
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transfers sulfate to the C6 of an already 4-O sulfated
GalNAc residue. Epimerization of GlcA residues is cata-
lysed by the product of the DSE gene, and its C2 pos-
ition can be sulfated by an uronyl-2-sulfotransferase
encoded by UST [40]. Analysis of differential transcrip-
tion of CS chain modification genes in this work showed
that this group undergoes further alterations: 4 out of 9
genes displayed relevant reduced relative abundance of
mRNA. The changes did not affect epimerization, but
did affect sulfation in all positions, in both metastatic
and non-metastatic tumors. UST transcription was
downregulated about 4 fold, which should reduce the
sulfation at C2 of IdoA. C6 sulfation of GalNAc
appeared to be greatly diminished since the two genes
involved, CHST3 and CHST7, were deregulated, on aver-
age, 8 fold. Finally, sulfation of C4 was also affected, as
evidenced by the fact that CHS12, one of the sulfotrans-
ferases with higher levels of transcription, appeared
downregulatred about 3 fold in non-metastatic and
nearly 10 fold in the metastatic IDCs. Interestingly,CHST11, which has been recently reported as highly
expressed in aggressive breast cancer cells and to be sig-
nificantly lower in less aggressive cancer lines [40], did
not show significant differences in this study.
HPSE is an endo-β-D-glucuronidase that cleaves spe-
cific β-D-glucouronosyl-N-acetyl-glucosaminyl linkages
[42]. Its expression is induced in all major types of
human cancer, and is often associated with reduced pa-
tient survival, increased tumor metastasis and higher
microvessel density [20]. Here, analysis of HPSE tran-
scripts in IDCs produced no significant differences des-
pite the use of two different pairs of probes located in
regions at a considerable distance from each other.
Alternative splicing has been reported to occur in the
non-coding regions of HPSE [20], and there is a possibil-
ity that this could influence the levels of protein expres-
sion. Two mRNA species that display the same ORF but
differ in the structure of their 50 end, HPSE1a and
HPSE1b, have been described [19]. In this study, qRT-
PCRanalysis indicated that the HPSE1a isoform was
expressed in both healthy and tumor tissues, and at
Fernández-Vega et al. BMC Cancer 2013, 13:24 Page 15 of 16
http://www.biomedcentral.com/1471-2407/13/24levels comparable to those determined in the coding re-
gion of HPSE. In contrast, HPSE1b was translated at
very low or undetectable levels.
Recently, regulatory elements have been described in
the 30 unstranslated region (UTR) of the HPSE gene [21].
A 185-bp sequence that mediates HPSE down-regulation
has been identified, which includes an adenine/uracil-rich
consensus element able to cause mRNA degradation.
Transcripts for both forms were detected in our study, al-
though shorter mRNA was the most abundant. The differ-
ences observed between tumors and healthy tissues were
not sufficient to reach significance, although when the
analysis was carried out considering the ratio of the rela-
tive expression levels of both forms (long form / short
form) however, the results showed statistically significant
values for metastatic tumors. This would appear to indi-
cate a shift towards a more stable form of mRNA in this
tumor type, which may affect the overexpression of the
protein by increasing its translation without an increase in
its transcription levels.
HPSE2 is a homologue of HPSE that lacks HS-
degrading activity, although it is able to interact with HS
with high affinity [20]. There are several proteins gener-
ated by alternative splicing, although only the wild-type,
HPSE2c, is secreted and binds with HS with very high
affinity, competing with HPSE [43]. HPSE2 is capable of
associating with HPSE and thus possibly modulates the
latter’s enzymatic activity and signaling properties. This
has resulted in an anti-metastatic feature being proposed
[20,43]. Analysis of HPSE2 transcription in tumors
showed a noticeable decline, 100% of the tumors being
affected, both metastatic and non metastatic. The down-
regulation was aproximatly 30 fold, and was detected
using probes common to all isoforms as well as probes
against exons 3 and 4, which can selectively detect
HPSE2c. These data were confirmed by immunohisto-
chemical studies where tissue arrays showed a noticeable
decrease in inmunoreactivity for all tumors analysed.
Conclusions
Analysis of the differential expression of the genes
involved in the biosynthesis of HSPGs in tumors indi-
cated that about 25% experienced significant changes in
their transcript levels. Although some variations were
detectable only in non metastatic tumors, most were
identified in both IDCs although several genes showed
more intense changes in metastatic tumors than in non-
metastatic, including PRCAN, CSGALNACT2, HS3ST4
and CHST12. The overexpression of HPSE in metastatic
tumors has been widely referenced in the literature, al-
though our results show that it did not appear to
undergo changes in levels of transcription, although its
protein levels could well be controlled by a more stable
mRNA isoform. In contrast, HPSE2, a homologue ofHPSE that is able to interact with HS with high affinity,
hence it being proposed to have anti-cancer properties,
exhibited strong underexpression in all the patients
studied, pointing to this gene having an important role
in breast tumor progression.
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